Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728830 · ClinicalTrials.gov registry record · Early Phase 1
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
A Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AA Secord.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT02728830: Completed Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, sponsored by AA Secord.
NCT02728830 is a Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer that has completed, run by AA Secord. The registered enrollment target is 39 participants, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728830, a Early Phase 1 study of Fallopian Tube Cancer and Epithelial Ovarian Cancer, has completed, sponsored by AA Secord.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
Primary Outcome
This outcome measures the change in tumor immune infiltrates post-pembrolizumab versus pre-pembrolizumab as measured by the PD-L1 Modified H-score. Histological score (H-score) is a score that is comprised of intensity and percentage of staining and is used for assessing amount of protein (in this case PD-L1) present in a tissue sample. H-score is determined by adding of the percentages of cell staining at each intensity level multiplied by the membrane intensity of staining (0 (no staining), 1
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (1)
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-06 |
| Est. Completion | 2022-01-31 |
| Phase | Early Phase 1 |
What the finished NCT02728830 record still lists
NCT02728830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 255-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (85% lower).
The record links to 5 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02728830 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02728830 about?
NCT02728830 is a clinical study titled "A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers". The ultimate goal of the study is to identify potential biomarkers, immune gene expression signatures, and co-stimulatory pathways that may be used to understand the effect of immune checkpoint inhibitors on gynecologic cancers.
What is the current status of trial NCT02728830?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 39 participants. The study started on 2016-06. Estimated completion is 2022-01-31.
What conditions does trial NCT02728830 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer, Gynecologic Neoplasms, Uterine Endometrial Cancer.
What interventions are being tested in trial NCT02728830?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02728830?
This trial is sponsored by AA Secord, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02728830 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02728830's enrollment target sits among peer trials
39 55th of 85 higher than 31 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Using Aspirin to Improve Immunological Features of Ovarian Tumors
RECRUITING · Early Phase 1
-
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
ACTIVE NOT RECRUITING · Early Phase 1
-
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
COMPLETED · Early Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia